Craig Munger, MD
Ophthalmic Plastic and Reconstructive Surgery · Zephyrhills, FLNPI 1922005883
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 66.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $162 and has fallen 62.5% since, to $61 in 2025. That places this record below the midpoint for ophthalmic plastic and reconstructive surgery clinicians in FL, where the typical reported total is $1,956.
Across 35 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$441
- AbbVie$58
- Johnson & Johnson Surgical Vision, Inc.$44
- Sight Sciences, Inc.$36
- Alcon$34
- Sun Pharmaceutical Industries Inc.$25
- plus $30 from 2 others
What the payments were for
- Food & beverage$667100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 22 | $441 |
| AbbVie | 4 | $58 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $44 |
| Sight Sciences, Inc. | 2 | $36 |
| Alcon | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $14 |
How this compares
$667 in reported general payments places this provider in the 25th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
See all ophthalmic plastic and reconstructive surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 1,056 | $13,217 |
| Methylprednisolone | 366 | $2,593 |
| Latanoprost | 42 | $610 |
| Prednisolone Acetate | 13 | $520 |
| ErythromycinErythromycin Base | 50 | $480 |
| MoxifloxacinMoxifloxacin Hcl | 23 | $424 |
| Timolol Maleate | 13 | $175 |
| Amoxicillin | 27 | $112 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Zephyrhills
- John FezzaVenice$3.6M
- Wendy LeeMiami$616K
- Jennifer MurdockMiami$316K
- Ana VictoriaMiami$130K
- Keshini ParbhuWindermere$102K
- Sara WesterMiami$78K
- Robert ApplebaumLakeland$39K
- Yasaman MohadjerSt Petersburg$6K
- William MackTampa$5K
- Gil EpsteinPlantation$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.